ArticleParasitology research2025
Restorative potential of melatonin during treatment of severe scabies in an experimental model.
Article in Parasitology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Scabies Treatment Failure: Beyond Drug Resistance and Toward a Multidimensional Understanding.Journal of tropical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key limitation of current synthetic treatments of scabies is their focus on eliminating the mites rather than addressing the body's immune response or tissue healing, potentially fostering drug resistance and prolonging recovery. Melatonin, with its anti-inflammatory, antioxidant, and antimicrobial properties, presents a potential solution. Consequently, this research seeks to assess the value of melatonin supplementation as complementary therapy in Sarcoptes scabiei mite infestation. The study included 25 male crossbreed rabbits, divided into five groups of five rabbits each: group I (a negative control); group II (a positive control); group III (infected and treated with melatonin); group IV (infected and treated with ivermectin); and group V (infected and treated with melatonin and ivermectin). Clinical and parasitological assessments were conducted from day 0 till day 28 post-treatment. Serum and tissue samples were collected at the end of day 28 post-treatment for subsequent histopathological, biochemical, and immunological analyses. Our research indicated that combining melatonin with ivermectin (group V) significantly accelerated clinical improvement compared to using ivermectin alone (group IV). Melatonin also lessened the side effects of ivermectin seen in group IV and effectively alleviated itching in group V. Skin analysis of group V revealed nearly full healing and the absence of mites, unlike group IV, which still showed inflammation and dead mites. Supporting these findings, blood tests in group V demonstrated a significant improvement in biochemical and immunological markers compared to group IV. Infestation with Sarcoptes mites disrupts the balance between oxidants and antioxidants and triggers systemic inflammation. Supplementing melatonin can help restore this balance and reduce inflammation, thereby accelerating cure in affected rabbits. Therefore, melatonin is suggested as an adjunct therapy with ivermectin, particularly in severe scabies cases, and future research should explore optimal dosages and treatment regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.